Clinical Trials
265 trialsSTARTRK-2
Hoffmann-La Roche
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
Ohio State University Comprehensive Cancer Center
PIKALO-1
Eli Lilly and Company
DESCENT-1
A2 Biotherapeutics Inc.
LEARN
University of Sydney
OvAR-Y
Washington University School of Medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
OP-NEU-101
Onchilles Pharma Inc
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
SHERLOCK
University Health Network, Toronto
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
University of Chicago
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology, Inc.
LIBRETTO-001
Eli Lilly and Company
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
ReRT
The New York Proton Center
FIBROTHERME
Association Francaise pour la Recherche Thermale
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Topical Diclofenac for Prevention of Radiation-induced Dermatitis
The Second Affiliated Hospital of Hainan Medical University
Feasibility Study of CBCT for IGRT in Cancer Patients
Varian, a Siemens Healthineers Company
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
MOMENTUM
UMC Utrecht
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
QVA-Mod
Hospices Civils de Lyon
Virtual Rehabilitation for Cancer Survivors
University Health Network, Toronto
ONE TEAM
Duke University
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
SCANDARE
Institut Curie
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
TAGNOT
Kidney Cancer Research Bureau
CAMPERR
Adela, Inc
SCORE
Natera, Inc.
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
ELEPHAS-05
Elephas
LIBRETTO-121
Eli Lilly and Company
CONFIGURE
Varian, a Siemens Healthineers Company
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis